Clearity presents work at AACR
Scientific director Dr. Deb Zajchowski and founder Dr. Laura Shawver presented Clearity Foundations work at the annual meeting of the American Association for Cancer Research on April 18, 2010.The ClearityFoundation is among the first to bring molecular profiling to cancer patients, the only foundation providing these services regardless of the patient's ability to pay and the only group focused on ovarian cancer!The poster, SELECTING PATIENTS for OVARIAN CANCER CLINICAL TRIALS by PROFILING TUMORS against a BROAD PANEL of MOLECULAR MARKERS, was a summary of the patient profiling work completed in 2009. Click here to view a copy of the poster presentation!
The poster presentation summarized work conducted on 58 patients using a panel of 24 drug targets and drug response markers. It confirmed that the complexity and heterogeneity observed at the genomic level is maintained at the protein level. With the exception of two markers, no drug targets are highly expressed in a large fraction of tumors. Profiling a large panel of targets for each patient tumor is not only feasible but it may be key to selecting appropriate treatment options including clinical trials. Individual patient profiles are currently interpreted by comparison with other ovarian tumor profiles stored in The ClearityFoundation database. As correlative data for marker expression and therapy response are generated, more informed and reliable interpretation of individual tumor results will be possible.
